Local view for "http://purl.org/linkedpolitics/eu/plenary/1999-12-15-Speech-3-088"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.19991215.6.3-088"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:translated text |
"Mr President, ladies and gentlemen, I appeared before the Committee on Industry on 6 December to present the results of the Research Council of 2 December. I informed the Committee that the ministers had agreed to a new supplementary research programme up to 2003, for the Petten High Flux Reactor in the Netherlands.
The Euratom Treaty does not provide for Parliament to be consulted. However, in accordance with the interinstitutional agreement between this House and the Council, the latter undertook to formalise its agreement only after having requested Parliament’s opinion.
This is the procedure which the Council has followed and in which the Commission is not involved. However, in view of its desire to keep Parliament informed, the Commission was careful to send its proposal to this House at the same time as to the Council. I now understand that the urgency with which this procedure has taken place has not actually allowed Parliament to satisfactorily express its opinion on this proposal. However, the Commission, as the body which will be responsible for implementing this programme, can only hope for its formal adoption.
The importance of this research reactor in the medical field in recent years cannot be ignored. The Petten High Flux Reactor has produced 60% of the isotopes needed for cancer diagnoses and therapies in European hospitals and other medical centres. Over six million diagnoses are made annually in Europe due to this work. In addition, the Community is conducting medical research in this reactor, particularly on the development of new brain tumour therapies.
Finally, I must point out that this programme is being financed by three Member States only, namely the Netherlands, Germany and France. Community financing is not being used. The High Flux Reactor also receives major financing from the European pharmaceutical industry.
On behalf of the Commission, I can only hope that Parliament will add its support to the Council’s. Having said this, I am happy to discuss this matter further with this House at a future date."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples